Sensitive immunogenicity testing begins with thoughtful assay design.

Developing anti-drug antibody (ADA) assays for biologics and biosimilars requires overcoming analytical challenges such as drug interference and soluble target binding. This poster highlights the development of an electrochemiluminescence (ECL)-based bridging assay for detecting antibodies to bevacizumab, demonstrating strategies for optimizing assay performance and supporting reliable immunogenicity assessments.

Key highlights include:

• Development of an ECL-based bridging assay for bevacizumab immunogenicity testing
• Strategies for improving drug tolerance and minimizing soluble VEGF interference
• Approaches for optimizing assay sensitivity, specificity, and robustness
• Considerations for supporting reliable ADA detection throughout clinical development
• Practical insights for immunogenicity testing of biologics and biosimilars

As biologic and biosimilar development continues to grow, robust ADA assays remain essential for generating reliable immunogenicity data. See how optimized assay design can overcome common analytical challenges and support successful clinical development.